Merel Jebbink
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 24, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib Treatment.
Journal: JTO clinical and research reports
Published: September 18, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study.
Journal: Neuro-oncology
Published: August 07, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 05, 2024
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC.
Journal: JTO clinical and research reports
Published: September 01, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Journal: EClinicalMedicine
Published: February 11, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
Journal: JTO clinical and research reports
Published: December 21, 2022
Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.
Journal: Pharmaceutical research
Published: March 03, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 14, 2022
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC.
Journal: JTO clinical and research reports
Published: July 29, 2021
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Journal: EBioMedicine
Published: July 23, 2020
The force of HER2 - A druggable target in NSCLC?
Journal: Cancer treatment reviews
Published: November 18, 2019
Last Updated: 09/26/2026